US FDA approves Korean interferon alpha

Published: 2010-11-08 06:57:00

Updated: 2010-11-08 06:57:00

Hanall Biopharma has recently announced it has received approval from the U.S. Food and Drug Administration to conduct phase II clinical trial of HanferonTM Inj. (interferon alpha) for the treatment of hepatitis C.

Last September, the company filed the IND application entitled “Phase 1b/2a, Op...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK